Skip to main content
Explore URMC

menu

Squamous Cell Carcinoma of the Head and Neck Cancer: PD 0332991 and Cetuximab in Patients With Incurable SCCHN

Research Question:
What is the maximum tolerated dose of palbociclib when given in combination with cetuximab? What are the effects of this drug combination and how effective is it?

Basic Study Information

Purpose:
If you participate in this study you will be taking palbociclib and cetuximab as treatment for your cancer. Palbociclib is taken by mouth once a day and cetuximab is given intravenously weekly.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02101034?term=Phase+I%2FII+of+the+addition+of+Palbociclib+to+Cetuximab&rank=2https://clinicaltrials.gov/ct2/show/NCT02101034?term=Phase+I%2FII+of+the+addition+of+Palbociclib+to+Cetuximab&rank=2
Study Reference #: UHAN17040

Lead Researcher (Principal Investigator)

Lead Researcher: Ronald Maggiore

Study Contact Information

Study Coordinator: Park Bogan
Phone: (585) 276-4415
Email: Park_Bogan@URMC.Rochester.edu

Additional Study Details

Return to Search